Table 7.
Prescription of the type of chemotherapy based on pathological stage and biology
| Stage | CMF-like | Anthracyclines | Anthracyclines + Taxanes | Taxanes |
|---|---|---|---|---|
| Luminal A | ||||
| IA* |
3 (25.0%) |
8 (66.7%) |
0 (0%) |
1 (8.3%) |
| IB** |
16 (27.1%) |
36 (61.0%) |
7 (11.9%) |
0 (0%) |
| II*** |
16 (7.5%) |
113 (53.1%) |
75 (35.2%) |
9 (4.2%) |
| III**** |
5 (7.4%) |
12 (17.6%) |
47 (69.1%) |
4 (5.9%) |
| Total |
40 (11.4%) |
169 (48.0%) |
129 (36.6%) |
14 (4.0%) |
| Luminal B | ||||
| A* |
1 (10.0%) |
9 (66.7%) |
0 (0%) |
0 (0%) |
| IB** |
7 (15.9%) |
31 (61.0%) |
7 (11.4%) |
1 (2.3%) |
| II*** |
10 (7.7%) |
67 (53.1%) |
44 (33.8%) |
9 (6.9%) |
| III**** |
0 (0%) |
9 (17.6%) |
36 (78.3%) |
1 (2.2%) |
| Total |
18 (7.8%) |
116 (50.4%) |
85 (37.0%) |
11 (4.8%) |
| HER2 | ||||
| IA* |
0 (0%) |
22 (88.0%) |
2 (8.0%) |
1 (4.0%) |
| IB** |
4 (5.2%) |
54 (70.1%) |
18 (23.4%) |
1 (1.3%) |
| II*** |
4 (3.3%) |
55 (45.1%) |
61 (50.0%) |
2 (1.6%) |
| III**** |
3 (6.7%) |
6 (13.3%) |
36 (80.0%) |
0 (0%) |
| Total |
11 (4.1%) |
137 (50.9%) |
117 (43.5%) |
4 (1.5%) |
| Triple negative | ||||
| IA* |
4 (23.5%) |
8 (47.1%) |
4 (23.5%) |
1 (5.9%) |
| IB** |
8 (14.3%) |
30 (53.6%) |
14 (25.0%) |
4 (7.1%) |
| II*** |
3 (4.0%) |
38 (50.7%) |
32 (42.7%) |
2 (2.7%) |
| III**** |
2 (15.4%) |
0 (0%) |
9 (69.2%) |
2 (15.4%) |
| Total | 17 (10.6%) | 76 (47.2%) | 59 (36.6%) | 9 (5.6%) |